



## Clinical trial results:

**Eficacia y seguridad de la rupatadina en la rinitis alérgica persistente y calidad de vida relacionada con la salud en niños de 6 a 11 años: Ensayo clínico aleatorizado, doble ciego y controlado con placebo.**

**“Efficacy and safety of Rupatadine in persistent allergic rhinitis and health-related quality of life in children age 6-11 years; A randomized, double blind, placebo-controlled clinical trial ”**

### Summary

EudraCT number	2008-005939-15
Trial protocol	HU ES
Global end of trial date	10 February 2010

### Results information

Result version number	v1 (current)
This version publication date	12 June 2022
First version publication date	12 June 2022
Summary attachment (see zip file)	Clinical Study Report Synopsis (DC04RUP308_CSR_Synopsis.pdf)

### Trial information

#### Trial identification

Sponsor protocol code	DC04/RUP/3/08
-----------------------	---------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	J. Uriach y Compañía S.A
Sponsor organisation address	Avinguda Camí Reial 51-57, Palau-Solità i Plegamans, Spain, 08184
Public contact	Daniel Peris, J. Uriach y Compañía S.A., daniel.peris@noucor.com
Scientific contact	Daniel Peris, J. Uriach y Compañía S.A., +34 682 576 455, daniel.peris@noucor.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	28 July 2010
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	10 February 2010
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The study objective is to assess the efficacy and safety of rupatadine solution over a period of 28 to 42 days in children between 6 and 11 years old with persistent allergic rhinitis.

The main efficacy endpoint will be the change in the total score of the patient symptoms (T4SS) over the 28 days of treatment with rupatadine solution (patient diary card reflective 24 hours symptoms, all days including the same visit days with the investigator).

Protection of trial subjects:

Before being enrolled in the clinical study, subjects/parent/guardian consented to participate after the nature, scope and possible consequences of the clinical study explained in a form understandable to them. The investigator provided the subject and parent/guardian with an information form on the product and the study characteristics that were read to and/or discussed with the subject and parent/guardian in an understandable way. In this document, the patients and their parents/guardians who were willing to consent to participate in this study were informed of the nature, extent, design and conduct of the study and their consent was obtained in writing prior to inclusion to the study schedule. Patients were given the opportunity to ask questions and were informed of their right to withdraw from the study at any time, for any reason.

After reading the informed consent document, the subject/parent/guardian gave consent in writing. The subject's consent confirmed at the time of consent by the personally dated signature of the subject and by the personally dated signature of the person conducting the informed consent discussions.

The original signed consent document was retained by the principal investigator.

The principal investigator did not undertake any measures specifically required only for the clinical study until valid consent was obtained.

The investigator did not include in the study any subject without previously obtaining written consent from him/her or from his/her legal representative.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	31 March 2009
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 12
Country: Number of subjects enrolled	Hungary: 89
Country: Number of subjects enrolled	South Africa: 218
Country: Number of subjects enrolled	Argentina: 41

Worldwide total number of subjects	360
EEA total number of subjects	101

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	359
Adolescents (12-17 years)	1
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

A total of 445 patients were screened in the study from 31 March 2009 to 16 December 2009 out of whom 360 (80.9%) were randomized to each treatment group (180 patients to the placebo group and 180 patients to the Rupatadine solution (1mg/ml) group).

### Pre-assignment

Screening details:

All children screening activities were required to be completed within 14 days prior to Day 0, unless otherwise specified

If children did not reach the score necessary to be randomized, they should have the chance of completing the selection diary during one more week, but being always in the maximum screening period of 14 days.

### Period 1

Period 1 title	overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor

Blinding implementation details:

Both active treatment and placebo were matched in pharmaceutical form, colour transparency and taste in order to keep the double-blind design

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo

Arm description: -

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo tablet every day

<b>Arm title</b>	Product test
------------------	--------------

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Rupatadine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

10 mg oral tablet every day

<b>Number of subjects in period 1</b>	Placebo	Product test
Started	180	180
Completed	161	164
Not completed	19	16
Consent withdrawn by subject	2	-
other reasons, not specified	10	-
Adverse event, non-fatal	1	-
unkown	-	3
Lost to follow-up	-	2
Lack of efficacy	1	3
Protocol deviation	5	8

## Baseline characteristics

## End points

### End points reporting groups

Reporting group title	Placebo
Reporting group description: -	
Reporting group title	Product test
Reporting group description: -	

### Primary: 28-day average change from baseline of the subjects' total 4 nasal symptoms score (T4SS)

End point title	28-day average change from baseline of the subjects' total 4 nasal symptoms score (T4SS)
End point description: The primary efficacy assessment was the 28-day average change from baseline of the subjects' total 4 symptoms score (T4SS): (1) nasal congestion, (2) sneezing, (3) rhinorrhea, and (4) itchy nose, mouth throat and/or ears in the ITT population.	
End point type	Primary
End point timeframe: 28 days	

End point values	Placebo	Product test		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	180		
Units: T4SS				
arithmetic mean (standard deviation)	4.7 (± 2.1)	4.2 (± 2.2)		

### Statistical analyses

Statistical analysis title	Ancova differences
Comparison groups	Placebo v Product test
Number of subjects included in analysis	360
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	= 0.018
Method	ANCOVA
Parameter estimate	Mean difference (net)

### Secondary: Change from baseline in the total 4 symptoms score (T4SS) after 42 days of treatment

End point title	Change from baseline in the total 4 symptoms score (T4SS) after 42 days of treatment
-----------------	--

End point description:	
Change from baseline in the total 4 symptoms score (T4SS) after 42 days of treatment	
End point type	Secondary
End point timeframe:	
42 days	

End point values	Placebo	Product test		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	180		
Units: T4SS				
arithmetic mean (standard deviation)	4.5 ( $\pm$ 2.1)	3.9 ( $\pm$ 2.2)		

### Statistical analyses

Statistical analysis title	Ancova difference
Comparison groups	Placebo v Product test
Number of subjects included in analysis	360
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	= 0.048
Method	ANCOVA

### Secondary: Change from baseline in the Total Symptoms Score

End point title	Change from baseline in the Total Symptoms Score
End point description:	
End point type	Secondary
End point timeframe:	
28 and 42 days of treatment	

End point values	Placebo	Product test		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	180		
Units: T5SS				
arithmetic mean (standard deviation)	5.4 ( $\pm$ 2.7)	4.6 ( $\pm$ 2.7)		

### Statistical analyses

No statistical analyses for this end point

---

**Secondary: Change in the daily score for each symptom (DSS)**

---

End point title	Change in the daily score for each symptom (DSS)
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

28 and 42 days

End point values	Placebo	Product test		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	180		
Units: DSS				
arithmetic mean (standard deviation)	1.2 ( $\pm$ 0.6)	1.1 ( $\pm$ 0.7)		

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Secondary: Mean value of the daily symptom scores (T4SS and T5SS)**

---

End point title	Mean value of the daily symptom scores (T4SS and T5SS)
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

42 days

End point values	Placebo	Product test		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	180		
Units: t4ss t5ss				
arithmetic mean (standard deviation)	3.8 ( $\pm$ 2.8)	3.3 ( $\pm$ 2.9)		

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Secondary: Time to beginning of action**

---

End point title	Time to beginning of action
-----------------	-----------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

NA

End point values	Placebo	Product test		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	180		
Units: hours	12	12		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Maximum value of the daily score of each symptom (DSSmax)

End point title	Maximum value of the daily score of each symptom (DSSmax)
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

28 days

End point values	Placebo	Product test		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	180		
Units: DSSmax				
arithmetic mean (standard deviation)	2.5 (± 0.7)	2.3 (± 0.8)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Maximum value of the daily total symptom score (T5SSmax).

End point title	Maximum value of the daily total symptom score (T5SSmax).
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

1 day

End point values	Placebo	Product test		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	180		
Units: T5ss				
arithmetic mean (standard deviation)	9.6 ( $\pm$ 3.1)	8.9 ( $\pm$ 3.1)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of days during the study period when the maximum daily score was from 0 to 1

End point title	Percentage of days during the study period when the maximum daily score was from 0 to 1
End point description:	
End point type	Secondary
End point timeframe:	
NA	

End point values	Placebo	Product test		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	180		
Units: percentage	37	43		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of days during the study period when the maximum daily score was 0

End point title	Percentage of days during the study period when the maximum daily score was 0
End point description:	
End point type	Secondary
End point timeframe:	
NA	

<b>End point values</b>	Placebo	Product test		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	180		
Units: percentage	6	11		

### Statistical analyses

No statistical analyses for this end point

### Secondary: patients requiring rescue medication

End point title	patients requiring rescue medication
End point description:	
End point type	Secondary
End point timeframe:	
42 days	

<b>End point values</b>	Placebo	Product test		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	180	180		
Units: patients	5	3		

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All serious adverse events were reported by the investigator to the monitor responsible for the clinical trial or to the Manager of Drug Safety at J. Uriach y Compañía, S.A. within 24hours after their knowledge.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	nk

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Reporting group title	Test product
-----------------------	--------------

Reporting group description: -

Serious adverse events	Placebo	Test product	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 180 (0.00%)	0 / 180 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	Placebo	Test product	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	54 / 180 (30.00%)	67 / 180 (37.22%)	
Injury, poisoning and procedural complications			
unknown			
subjects affected / exposed	1 / 180 (0.56%)	5 / 180 (2.78%)	
occurrences (all)	1	5	
Nervous system disorders			
Headache			
subjects affected / exposed	10 / 180 (5.56%)	23 / 180 (12.78%)	
occurrences (all)	10	24	
General disorders and administration site conditions			

unk subjects affected / exposed occurrences (all)	2 / 180 (1.11%) 2	5 / 180 (2.78%) 5	
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	1 / 180 (0.56%) 8	5 / 180 (2.78%) 9	
unk subjects affected / exposed occurrences (all)	7 / 180 (3.89%) 8	4 / 180 (2.22%) 9	
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	7 / 180 (3.89%) 18	7 / 180 (3.89%) 15	
Epistaxis subjects affected / exposed occurrences (all)	5 / 180 (2.78%) 18	1 / 180 (0.56%) 15	
UNK subjects affected / exposed occurrences (all)	6 / 180 (3.33%) 18	7 / 180 (3.89%) 15	
Skin and subcutaneous tissue disorders			
Eczema subjects affected / exposed occurrences (all)	1 / 180 (0.56%) 4	4 / 180 (2.22%) 7	
unk subjects affected / exposed occurrences (all)	3 / 180 (1.67%) 4	3 / 180 (1.67%) 7	
Infections and infestations			
Influenza subjects affected / exposed occurrences (all)	2 / 180 (1.11%) 27	6 / 180 (3.33%) 26	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	3 / 180 (1.67%) 27	5 / 180 (2.78%) 26	
Pharyngitis			

subjects affected / exposed	3 / 180 (1.67%)	4 / 180 (2.22%)	
occurrences (all)	27	26	
UNK			
subjects affected / exposed	19 / 180 (10.56%)	11 / 180 (6.11%)	
occurrences (all)	26	27	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported